NHWA(SZ:002262) Xin Lang Cai Jing·2025-09-24 05:59Core Viewpoint - Enhua Pharmaceutical experienced a 5.06% increase in stock price, reaching 28.65 CNY per share, with a trading volume of 354 million CNY and a market capitalization of 29.102 billion CNY as of September 24 [1] Company Overview - Enhua Pharmaceutical, established on March 29, 1999, and listed on July 23, 2008, is located in Xuzhou Economic and Technological Development Zone, Jiangsu Province [1] - The company's main business includes pharmaceutical production, research and development, and sales, which encompass the sales of its manufactured formulations as well as wholesale and retail pharmaceutical businesses [1] Revenue Composition - The revenue composition of Enhua Pharmaceutical is as follows: - Anesthetics: 54.28% - Psychotropic drugs: 20.63% - Commercial pharmaceuticals: 13.08% - Neurological drugs: 5.51% - Raw materials: 2.98% - Other sales: 2.41% - Other trade and services: 0.58% - Miscellaneous: 0.52% [1] Shareholder Information - Among the top ten circulating shareholders of Enhua Pharmaceutical, a fund under Southern Fund ranks, with the Southern CSI 500 ETF (510500) newly entering the top ten in the second quarter, holding 9.0517 million shares, which is 1.03% of the circulating shares [2] - The estimated floating profit from this investment is approximately 12.4913 million CNY [2] Fund Performance - The Southern CSI 500 ETF (510500), managed by Luo Wenjie, has a total asset size of 113.438 billion CNY and has achieved a year-to-date return of 27.04%, ranking 1786 out of 4220 in its category [2] - Over the past year, the fund has returned 61.77%, ranking 1494 out of 3814, and since its inception, it has achieved a return of 141.04% [2]